Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Prostatic Neoplasms | 120 | 2024 | 11094 | 7.910 |
Why?
|
Carcinoma, Neuroendocrine | 24 | 2024 | 343 | 6.350 |
Why?
|
Neuroendocrine Tumors | 30 | 2024 | 657 | 4.970 |
Why?
|
Receptors, Androgen | 34 | 2024 | 1088 | 3.840 |
Why?
|
Gene Expression Regulation, Neoplastic | 38 | 2024 | 8612 | 2.060 |
Why?
|
Androgen Receptor Antagonists | 9 | 2024 | 123 | 1.720 |
Why?
|
Drug Resistance, Neoplasm | 21 | 2024 | 5336 | 1.390 |
Why?
|
Adenocarcinoma | 25 | 2024 | 6363 | 1.380 |
Why?
|
Androgen Antagonists | 19 | 2024 | 1411 | 1.360 |
Why?
|
Phenylthiohydantoin | 11 | 2024 | 206 | 1.360 |
Why?
|
Orchiectomy | 8 | 2020 | 465 | 1.340 |
Why?
|
Prostate | 14 | 2023 | 1758 | 1.220 |
Why?
|
Neoplastic Cells, Circulating | 6 | 2022 | 949 | 1.210 |
Why?
|
Carcinoma, Small Cell | 7 | 2024 | 420 | 1.090 |
Why?
|
Glutamate Carboxypeptidase II | 2 | 2024 | 90 | 1.070 |
Why?
|
Male | 165 | 2024 | 363935 | 0.940 |
Why?
|
Cell Line, Tumor | 48 | 2024 | 17071 | 0.920 |
Why?
|
Benzamides | 11 | 2024 | 1376 | 0.880 |
Why?
|
Organoids | 9 | 2022 | 740 | 0.880 |
Why?
|
Nitriles | 13 | 2024 | 981 | 0.860 |
Why?
|
Antigens, Surface | 3 | 2024 | 1616 | 0.850 |
Why?
|
Tumor Microenvironment | 9 | 2024 | 3942 | 0.830 |
Why?
|
Neoplasm Metastasis | 21 | 2024 | 4887 | 0.810 |
Why?
|
Neuroendocrine Cells | 6 | 2024 | 61 | 0.790 |
Why?
|
Cell Lineage | 9 | 2024 | 2573 | 0.760 |
Why?
|
Molecular Targeted Therapy | 9 | 2022 | 2824 | 0.730 |
Why?
|
Disease Progression | 22 | 2022 | 13616 | 0.660 |
Why?
|
Humans | 183 | 2024 | 766117 | 0.660 |
Why?
|
Epigenesis, Genetic | 14 | 2024 | 3818 | 0.650 |
Why?
|
Germ-Line Mutation | 5 | 2020 | 1885 | 0.650 |
Why?
|
Antineoplastic Agents | 21 | 2024 | 13635 | 0.640 |
Why?
|
Familial Mediterranean Fever | 1 | 2019 | 67 | 0.610 |
Why?
|
Prostatectomy | 9 | 2024 | 1786 | 0.600 |
Why?
|
Azepines | 3 | 2018 | 328 | 0.590 |
Why?
|
Genomics | 11 | 2022 | 5926 | 0.570 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 13 | 2024 | 11859 | 0.560 |
Why?
|
DNA Methylation | 9 | 2024 | 4425 | 0.530 |
Why?
|
Retinoblastoma | 1 | 2019 | 316 | 0.530 |
Why?
|
Retinoblastoma Binding Proteins | 6 | 2024 | 101 | 0.520 |
Why?
|
Cisplatin | 4 | 2020 | 1654 | 0.510 |
Why?
|
Prostate-Specific Antigen | 9 | 2024 | 2463 | 0.510 |
Why?
|
Neoplasm Proteins | 5 | 2020 | 3594 | 0.500 |
Why?
|
Molecular Biology | 1 | 2019 | 573 | 0.490 |
Why?
|
Nuclear Proteins | 9 | 2024 | 5791 | 0.470 |
Why?
|
Prednisone | 4 | 2024 | 1566 | 0.470 |
Why?
|
Microsatellite Instability | 3 | 2019 | 726 | 0.470 |
Why?
|
Mutation | 24 | 2024 | 30209 | 0.470 |
Why?
|
DNA Mismatch Repair | 2 | 2018 | 432 | 0.460 |
Why?
|
Tumor Suppressor Protein p53 | 5 | 2024 | 2946 | 0.460 |
Why?
|
Cell Differentiation | 8 | 2024 | 11642 | 0.450 |
Why?
|
Gene Dosage | 3 | 2015 | 1213 | 0.450 |
Why?
|
Bone Neoplasms | 6 | 2020 | 2559 | 0.440 |
Why?
|
Genes, myc | 2 | 2016 | 391 | 0.440 |
Why?
|
Taxoids | 4 | 2020 | 665 | 0.440 |
Why?
|
Gene Expression Profiling | 11 | 2023 | 9527 | 0.420 |
Why?
|
Medical Oncology | 5 | 2022 | 2339 | 0.400 |
Why?
|
PTEN Phosphohydrolase | 3 | 2020 | 1117 | 0.390 |
Why?
|
Xenograft Model Antitumor Assays | 11 | 2020 | 3604 | 0.380 |
Why?
|
DNA Repair | 6 | 2018 | 2048 | 0.380 |
Why?
|
Neoplasms | 13 | 2023 | 22344 | 0.380 |
Why?
|
Signal Transduction | 18 | 2024 | 23605 | 0.370 |
Why?
|
DNA Mutational Analysis | 4 | 2019 | 4112 | 0.370 |
Why?
|
SOXB1 Transcription Factors | 5 | 2021 | 283 | 0.360 |
Why?
|
Pyrrolidines | 1 | 2012 | 337 | 0.340 |
Why?
|
Prognosis | 18 | 2024 | 29912 | 0.340 |
Why?
|
Intracellular Signaling Peptides and Proteins | 2 | 2022 | 2879 | 0.340 |
Why?
|
Proto-Oncogene Proteins c-myc | 2 | 2017 | 998 | 0.330 |
Why?
|
Neoplasm Staging | 11 | 2024 | 11200 | 0.320 |
Why?
|
Hormones | 3 | 2023 | 865 | 0.320 |
Why?
|
Gene Deletion | 1 | 2016 | 2667 | 0.320 |
Why?
|
High-Throughput Nucleotide Sequencing | 6 | 2021 | 3665 | 0.310 |
Why?
|
Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2013 | 388 | 0.310 |
Why?
|
Cell Transdifferentiation | 4 | 2019 | 186 | 0.310 |
Why?
|
DNA Copy Number Variations | 3 | 2022 | 2045 | 0.310 |
Why?
|
Sequence Analysis, DNA | 4 | 2013 | 4780 | 0.290 |
Why?
|
Pyrimidines | 3 | 2018 | 3050 | 0.290 |
Why?
|
Antineoplastic Agents, Hormonal | 5 | 2021 | 1535 | 0.290 |
Why?
|
Androgens | 4 | 2024 | 1278 | 0.280 |
Why?
|
Mice | 29 | 2024 | 81839 | 0.280 |
Why?
|
DNA Helicases | 3 | 2022 | 852 | 0.280 |
Why?
|
Ubiquitin-Protein Ligases | 6 | 2024 | 1897 | 0.270 |
Why?
|
Genetic Testing | 2 | 2020 | 3594 | 0.260 |
Why?
|
Neoplasm Recurrence, Local | 7 | 2024 | 9378 | 0.260 |
Why?
|
Veterans | 1 | 2020 | 2667 | 0.250 |
Why?
|
Animals | 36 | 2024 | 168800 | 0.250 |
Why?
|
Practice Guidelines as Topic | 5 | 2024 | 7424 | 0.250 |
Why?
|
Biopsy | 4 | 2024 | 6768 | 0.240 |
Why?
|
Immunotherapy | 4 | 2021 | 4746 | 0.240 |
Why?
|
Protein Kinase Inhibitors | 7 | 2022 | 5695 | 0.240 |
Why?
|
Neoadjuvant Therapy | 3 | 2024 | 2897 | 0.240 |
Why?
|
Neoplasms, Second Primary | 1 | 2012 | 1056 | 0.230 |
Why?
|
Genomic Instability | 2 | 2019 | 716 | 0.230 |
Why?
|
Neoplasms, Hormone-Dependent | 2 | 2021 | 409 | 0.230 |
Why?
|
Androstenes | 4 | 2024 | 177 | 0.230 |
Why?
|
Cyclin-Dependent Kinase 2 | 1 | 2024 | 185 | 0.230 |
Why?
|
E2F1 Transcription Factor | 2 | 2021 | 183 | 0.220 |
Why?
|
Liver Neoplasms | 2 | 2017 | 4352 | 0.210 |
Why?
|
Receptors, CXCR | 1 | 2023 | 52 | 0.210 |
Why?
|
Mice, SCID | 6 | 2019 | 2626 | 0.210 |
Why?
|
Membrane Proteins | 2 | 2022 | 7850 | 0.210 |
Why?
|
Transcription Factors | 6 | 2023 | 12130 | 0.210 |
Why?
|
Trypsin Inhibitor, Kazal Pancreatic | 2 | 2020 | 30 | 0.210 |
Why?
|
Mice, Inbred NOD | 5 | 2019 | 1837 | 0.200 |
Why?
|
Carbolines | 1 | 2024 | 288 | 0.200 |
Why?
|
Biopsy, Needle | 3 | 2018 | 1613 | 0.200 |
Why?
|
Aged, 80 and over | 18 | 2024 | 59515 | 0.190 |
Why?
|
Tumor Cells, Cultured | 3 | 2020 | 6102 | 0.190 |
Why?
|
Homeodomain Proteins | 4 | 2019 | 2430 | 0.190 |
Why?
|
Transcription, Genetic | 6 | 2021 | 7600 | 0.190 |
Why?
|
Treatment Outcome | 14 | 2024 | 65219 | 0.190 |
Why?
|
Neoplasm Invasiveness | 4 | 2021 | 3602 | 0.190 |
Why?
|
Aged | 31 | 2024 | 171219 | 0.190 |
Why?
|
Proteins | 4 | 2021 | 5995 | 0.180 |
Why?
|
Carcinoma, Transitional Cell | 2 | 2019 | 789 | 0.180 |
Why?
|
Lutetium | 2 | 2019 | 38 | 0.180 |
Why?
|
Neoplasms, Complex and Mixed | 2 | 2018 | 35 | 0.180 |
Why?
|
Middle Aged | 30 | 2024 | 223083 | 0.180 |
Why?
|
Glutamates | 1 | 2022 | 384 | 0.180 |
Why?
|
Hepatocyte Nuclear Factor 3-alpha | 1 | 2021 | 167 | 0.180 |
Why?
|
DNA Repair-Deficiency Disorders | 1 | 2020 | 37 | 0.170 |
Why?
|
Proto-Oncogene Proteins c-pim-1 | 1 | 2020 | 31 | 0.170 |
Why?
|
Calcium-Calmodulin-Dependent Protein Kinases | 1 | 2021 | 489 | 0.170 |
Why?
|
Kidney Neoplasms | 3 | 2022 | 4282 | 0.170 |
Why?
|
Molecular Probes | 1 | 2022 | 309 | 0.170 |
Why?
|
Platinum Compounds | 1 | 2020 | 94 | 0.170 |
Why?
|
Survival Rate | 5 | 2021 | 12827 | 0.170 |
Why?
|
Pancreatic Neoplasms | 2 | 2017 | 5454 | 0.170 |
Why?
|
Anemia, Myelophthisic | 1 | 2019 | 6 | 0.160 |
Why?
|
Receptors, Notch | 1 | 2024 | 751 | 0.160 |
Why?
|
Urea | 1 | 2022 | 449 | 0.160 |
Why?
|
Benzodiazepinones | 1 | 2019 | 50 | 0.160 |
Why?
|
Prospective Studies | 10 | 2024 | 54812 | 0.160 |
Why?
|
Retinoblastoma Protein | 2 | 2021 | 666 | 0.160 |
Why?
|
Radioisotopes | 2 | 2019 | 498 | 0.160 |
Why?
|
DNA, Neoplasm | 2 | 2021 | 1739 | 0.160 |
Why?
|
Genes, Retinoblastoma | 1 | 2019 | 125 | 0.160 |
Why?
|
Organ Culture Techniques | 2 | 2021 | 788 | 0.160 |
Why?
|
Tristetraprolin | 1 | 2018 | 40 | 0.160 |
Why?
|
Glycoprotein Hormones, alpha Subunit | 1 | 2018 | 95 | 0.160 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2019 | 109 | 0.160 |
Why?
|
Protein Kinase C | 2 | 2024 | 1205 | 0.160 |
Why?
|
Kruppel-Like Transcription Factors | 1 | 2021 | 506 | 0.150 |
Why?
|
Smad3 Protein | 1 | 2019 | 165 | 0.150 |
Why?
|
Nickel | 1 | 2019 | 126 | 0.150 |
Why?
|
Neuropeptide Y | 1 | 2019 | 194 | 0.150 |
Why?
|
Disease Management | 2 | 2021 | 2531 | 0.150 |
Why?
|
Ureteral Neoplasms | 1 | 2019 | 106 | 0.150 |
Why?
|
Pancytopenia | 1 | 2019 | 102 | 0.150 |
Why?
|
Oncogene Proteins | 2 | 2013 | 711 | 0.150 |
Why?
|
Mass Screening | 2 | 2022 | 5450 | 0.150 |
Why?
|
Repressor Proteins | 3 | 2024 | 2974 | 0.150 |
Why?
|
DNA-Binding Proteins | 5 | 2024 | 9601 | 0.150 |
Why?
|
Cohort Studies | 12 | 2021 | 41684 | 0.140 |
Why?
|
Small Cell Lung Carcinoma | 1 | 2022 | 453 | 0.140 |
Why?
|
Colchicine | 1 | 2019 | 256 | 0.140 |
Why?
|
Drug Therapy | 1 | 2020 | 504 | 0.140 |
Why?
|
Hepatocyte Nuclear Factor 4 | 1 | 2017 | 126 | 0.140 |
Why?
|
Fanconi Anemia Complementation Group A Protein | 1 | 2017 | 51 | 0.140 |
Why?
|
Microtubule-Associated Proteins | 1 | 2022 | 1068 | 0.140 |
Why?
|
Lysine | 1 | 2022 | 994 | 0.140 |
Why?
|
Cell Cycle Proteins | 3 | 2024 | 3436 | 0.140 |
Why?
|
Phthalazines | 2 | 2019 | 397 | 0.140 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2021 | 878 | 0.140 |
Why?
|
Carcinoma, Renal Cell | 2 | 2022 | 3186 | 0.140 |
Why?
|
Urologic Neoplasms | 1 | 2020 | 312 | 0.140 |
Why?
|
POU Domain Factors | 1 | 2016 | 47 | 0.140 |
Why?
|
Hepatocyte Nuclear Factor 1-alpha | 1 | 2017 | 175 | 0.130 |
Why?
|
Pathology, Molecular | 1 | 2019 | 329 | 0.130 |
Why?
|
Drug Screening Assays, Antitumor | 2 | 2017 | 715 | 0.130 |
Why?
|
Neural Cell Adhesion Molecule L1 | 1 | 2016 | 44 | 0.130 |
Why?
|
Genes, Synthetic | 1 | 2016 | 88 | 0.130 |
Why?
|
Phenotype | 8 | 2022 | 16716 | 0.130 |
Why?
|
Genes, Lethal | 1 | 2016 | 224 | 0.130 |
Why?
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2020 | 384 | 0.130 |
Why?
|
Epigenomics | 2 | 2021 | 959 | 0.130 |
Why?
|
Cytodiagnosis | 2 | 2017 | 450 | 0.130 |
Why?
|
Feedback, Physiological | 1 | 2018 | 480 | 0.130 |
Why?
|
Retrospective Studies | 10 | 2024 | 81565 | 0.120 |
Why?
|
Early Detection of Cancer | 3 | 2022 | 3238 | 0.120 |
Why?
|
Genetic Heterogeneity | 1 | 2019 | 735 | 0.120 |
Why?
|
Chromosomal Proteins, Non-Histone | 1 | 2020 | 723 | 0.120 |
Why?
|
Genes, Neoplasm | 1 | 2017 | 369 | 0.120 |
Why?
|
Serine | 1 | 2019 | 828 | 0.120 |
Why?
|
Down-Regulation | 2 | 2019 | 2927 | 0.120 |
Why?
|
Leukocyte Count | 1 | 2019 | 1605 | 0.120 |
Why?
|
Terminology as Topic | 3 | 2020 | 1536 | 0.120 |
Why?
|
Ependymoma | 1 | 2017 | 310 | 0.120 |
Why?
|
Patient Selection | 4 | 2015 | 4249 | 0.120 |
Why?
|
Cell Survival | 3 | 2020 | 5747 | 0.120 |
Why?
|
Cadherins | 2 | 2023 | 900 | 0.110 |
Why?
|
Immunohistochemistry | 6 | 2022 | 11035 | 0.110 |
Why?
|
Isoenzymes | 1 | 2019 | 1688 | 0.110 |
Why?
|
INDEL Mutation | 1 | 2015 | 267 | 0.110 |
Why?
|
Genes, Tumor Suppressor | 1 | 2018 | 1060 | 0.110 |
Why?
|
Time Factors | 5 | 2020 | 40108 | 0.110 |
Why?
|
Disease Models, Animal | 5 | 2022 | 18321 | 0.110 |
Why?
|
Culture Techniques | 1 | 2014 | 515 | 0.110 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2015 | 259 | 0.110 |
Why?
|
Autopsy | 1 | 2017 | 1011 | 0.110 |
Why?
|
GPI-Linked Proteins | 1 | 2015 | 472 | 0.110 |
Why?
|
Chromatin | 2 | 2022 | 2981 | 0.110 |
Why?
|
Lung Neoplasms | 5 | 2022 | 13483 | 0.110 |
Why?
|
Forecasting | 1 | 2022 | 2936 | 0.110 |
Why?
|
Gene Regulatory Networks | 1 | 2021 | 1750 | 0.100 |
Why?
|
Feasibility Studies | 2 | 2015 | 5300 | 0.100 |
Why?
|
Computational Biology | 2 | 2015 | 3565 | 0.100 |
Why?
|
Cell Proliferation | 7 | 2024 | 10433 | 0.100 |
Why?
|
Fixatives | 1 | 2012 | 90 | 0.100 |
Why?
|
Mutagenesis | 1 | 2016 | 1227 | 0.100 |
Why?
|
Databases, Genetic | 1 | 2019 | 1756 | 0.100 |
Why?
|
Survival Analysis | 3 | 2019 | 10087 | 0.100 |
Why?
|
Enhancer Elements, Genetic | 1 | 2019 | 1363 | 0.100 |
Why?
|
Oncogenes | 1 | 2018 | 1232 | 0.100 |
Why?
|
Genetic Predisposition to Disease | 6 | 2019 | 18076 | 0.100 |
Why?
|
Purine-Nucleoside Phosphorylase | 1 | 2012 | 28 | 0.100 |
Why?
|
Oncogene Proteins, Fusion | 2 | 2020 | 1609 | 0.100 |
Why?
|
Androstenols | 1 | 2011 | 25 | 0.100 |
Why?
|
Molecular Diagnostic Techniques | 2 | 2013 | 614 | 0.100 |
Why?
|
Gene Amplification | 2 | 2014 | 1088 | 0.090 |
Why?
|
Sarcoma | 1 | 2022 | 1801 | 0.090 |
Why?
|
Mice, Knockout | 4 | 2021 | 14456 | 0.090 |
Why?
|
Paraffin Embedding | 1 | 2012 | 302 | 0.090 |
Why?
|
Tissue Fixation | 1 | 2012 | 245 | 0.090 |
Why?
|
Tumor Suppressor Proteins | 2 | 2019 | 2795 | 0.090 |
Why?
|
Immunoconjugates | 1 | 2019 | 976 | 0.090 |
Why?
|
Genome, Human | 4 | 2021 | 4443 | 0.090 |
Why?
|
Formaldehyde | 1 | 2012 | 360 | 0.090 |
Why?
|
Receptor, erbB-2 | 1 | 2021 | 2593 | 0.090 |
Why?
|
Trans-Activators | 2 | 2024 | 2849 | 0.090 |
Why?
|
Immunophenotyping | 1 | 2015 | 1865 | 0.090 |
Why?
|
Chromosomes, Human, Pair 15 | 1 | 2012 | 361 | 0.090 |
Why?
|
Chromosomes, Human, Pair 12 | 1 | 2012 | 432 | 0.090 |
Why?
|
Neuroblastoma | 2 | 2021 | 1263 | 0.090 |
Why?
|
Gene Targeting | 1 | 2014 | 840 | 0.090 |
Why?
|
Melanoma | 2 | 2022 | 5695 | 0.090 |
Why?
|
Estrogen Receptor alpha | 1 | 2014 | 580 | 0.090 |
Why?
|
Insulin Resistance | 1 | 2024 | 3988 | 0.090 |
Why?
|
Chromosomes, Human, Pair 9 | 1 | 2012 | 533 | 0.080 |
Why?
|
Introns | 1 | 2012 | 965 | 0.080 |
Why?
|
Up-Regulation | 4 | 2020 | 4133 | 0.080 |
Why?
|
Radioimmunotherapy | 1 | 2010 | 93 | 0.080 |
Why?
|
Consensus | 3 | 2024 | 3202 | 0.080 |
Why?
|
Neoplastic Stem Cells | 3 | 2022 | 1351 | 0.080 |
Why?
|
Genetic Association Studies | 1 | 2019 | 2744 | 0.080 |
Why?
|
Piperazines | 2 | 2019 | 2547 | 0.080 |
Why?
|
Oligonucleotide Array Sequence Analysis | 2 | 2020 | 3796 | 0.080 |
Why?
|
Positron-Emission Tomography | 2 | 2023 | 6545 | 0.080 |
Why?
|
Neoplasm Transplantation | 3 | 2019 | 2010 | 0.080 |
Why?
|
Mice, Transgenic | 5 | 2021 | 9540 | 0.080 |
Why?
|
Kaplan-Meier Estimate | 4 | 2020 | 6506 | 0.080 |
Why?
|
Venous Thromboembolism | 1 | 2021 | 1883 | 0.080 |
Why?
|
Treatment Failure | 2 | 2011 | 2653 | 0.070 |
Why?
|
Intercellular Signaling Peptides and Proteins | 1 | 2015 | 1656 | 0.070 |
Why?
|
Cell Transformation, Neoplastic | 2 | 2021 | 2838 | 0.070 |
Why?
|
Bone Density Conservation Agents | 1 | 2015 | 791 | 0.070 |
Why?
|
Research | 1 | 2016 | 1975 | 0.070 |
Why?
|
Urinary Bladder Neoplasms | 2 | 2017 | 2176 | 0.070 |
Why?
|
Nerve Tissue Proteins | 2 | 2020 | 4399 | 0.070 |
Why?
|
Bone and Bones | 1 | 2017 | 2555 | 0.070 |
Why?
|
Mice, Nude | 3 | 2019 | 3610 | 0.070 |
Why?
|
Stem Cells | 1 | 2020 | 3537 | 0.070 |
Why?
|
Chromosome Deletion | 1 | 2012 | 1384 | 0.070 |
Why?
|
Organ Transplantation | 1 | 2017 | 1172 | 0.070 |
Why?
|
Loss of Heterozygosity | 2 | 2020 | 663 | 0.070 |
Why?
|
Models, Genetic | 1 | 2016 | 3448 | 0.070 |
Why?
|
Models, Biological | 2 | 2020 | 9445 | 0.070 |
Why?
|
Chromosome Aberrations | 1 | 2013 | 1775 | 0.070 |
Why?
|
Exons | 1 | 2012 | 2393 | 0.070 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2015 | 2455 | 0.070 |
Why?
|
Follow-Up Studies | 4 | 2021 | 39243 | 0.070 |
Why?
|
Evidence-Based Medicine | 2 | 2024 | 3690 | 0.070 |
Why?
|
Neutrophils | 1 | 2019 | 3771 | 0.060 |
Why?
|
Base Sequence | 1 | 2017 | 12405 | 0.060 |
Why?
|
Drug Discovery | 1 | 2013 | 1065 | 0.060 |
Why?
|
Combined Modality Therapy | 1 | 2017 | 8525 | 0.060 |
Why?
|
Gene Expression | 2 | 2022 | 7582 | 0.060 |
Why?
|
Academic Medical Centers | 1 | 2015 | 2782 | 0.060 |
Why?
|
Sequence Analysis, RNA | 3 | 2019 | 2039 | 0.060 |
Why?
|
Receptor Tyrosine Kinase-like Orphan Receptors | 1 | 2024 | 43 | 0.060 |
Why?
|
Phylogeny | 2 | 2022 | 2838 | 0.060 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2022 | 5388 | 0.060 |
Why?
|
Reproducibility of Results | 3 | 2020 | 20137 | 0.060 |
Why?
|
Paneth Cells | 2 | 2014 | 99 | 0.060 |
Why?
|
Insulin | 1 | 2018 | 6604 | 0.050 |
Why?
|
Risk Assessment | 3 | 2020 | 24276 | 0.050 |
Why?
|
Epithelial-Mesenchymal Transition | 2 | 2021 | 752 | 0.050 |
Why?
|
Promoter Regions, Genetic | 3 | 2021 | 5784 | 0.050 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2015 | 10737 | 0.050 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 2 | 2020 | 1407 | 0.050 |
Why?
|
Dioxygenases | 1 | 2024 | 354 | 0.050 |
Why?
|
Transcriptional Activation | 2 | 2021 | 1743 | 0.050 |
Why?
|
Receptors, Kainic Acid | 1 | 2022 | 91 | 0.050 |
Why?
|
Predictive Value of Tests | 2 | 2015 | 15403 | 0.050 |
Why?
|
Ligands | 2 | 2022 | 3274 | 0.050 |
Why?
|
T-Lymphocytes | 1 | 2019 | 10260 | 0.050 |
Why?
|
Homeostasis | 1 | 2012 | 3338 | 0.050 |
Why?
|
Binding Sites | 2 | 2022 | 6001 | 0.050 |
Why?
|
Progesterone Reductase | 1 | 2020 | 14 | 0.050 |
Why?
|
Steroid Isomerases | 1 | 2020 | 19 | 0.050 |
Why?
|
MAP Kinase Kinase 1 | 1 | 2022 | 330 | 0.050 |
Why?
|
Aneuploidy | 1 | 2024 | 576 | 0.050 |
Why?
|
Cell Nucleus | 2 | 2021 | 2864 | 0.040 |
Why?
|
Enzyme Inhibitors | 1 | 2011 | 3722 | 0.040 |
Why?
|
Clinical Trials as Topic | 1 | 2017 | 8038 | 0.040 |
Why?
|
Molecular Conformation | 1 | 2022 | 539 | 0.040 |
Why?
|
Transcription Factor AP-1 | 1 | 2022 | 322 | 0.040 |
Why?
|
Hormone Antagonists | 1 | 2020 | 109 | 0.040 |
Why?
|
L-Lactate Dehydrogenase | 1 | 2021 | 411 | 0.040 |
Why?
|
Delphi Technique | 1 | 2024 | 893 | 0.040 |
Why?
|
RNA-Binding Proteins | 2 | 2022 | 1883 | 0.040 |
Why?
|
Casein Kinase I | 1 | 2020 | 46 | 0.040 |
Why?
|
Indolizines | 1 | 2019 | 29 | 0.040 |
Why?
|
Disease-Free Survival | 2 | 2022 | 6840 | 0.040 |
Why?
|
Mice, Inbred C57BL | 4 | 2021 | 22341 | 0.040 |
Why?
|
Cyclic N-Oxides | 1 | 2019 | 71 | 0.040 |
Why?
|
Quality of Life | 1 | 2021 | 13468 | 0.040 |
Why?
|
Case-Control Studies | 4 | 2019 | 22228 | 0.040 |
Why?
|
Pyridinium Compounds | 1 | 2019 | 80 | 0.040 |
Why?
|
Ultracentrifugation | 1 | 2019 | 155 | 0.040 |
Why?
|
Carbazoles | 1 | 2021 | 229 | 0.040 |
Why?
|
Phosphoramide Mustards | 1 | 2019 | 18 | 0.040 |
Why?
|
Platinum | 1 | 2020 | 219 | 0.040 |
Why?
|
Co-Repressor Proteins | 1 | 2020 | 190 | 0.040 |
Why?
|
Receptors, Dopamine D2 | 1 | 2021 | 471 | 0.040 |
Why?
|
Alternative Splicing | 2 | 2016 | 1103 | 0.040 |
Why?
|
Octamer Transcription Factor-3 | 1 | 2020 | 220 | 0.040 |
Why?
|
Cyclin-Dependent Kinase 5 | 1 | 2019 | 110 | 0.040 |
Why?
|
Muscular Atrophy | 1 | 2022 | 335 | 0.040 |
Why?
|
RNA Interference | 2 | 2021 | 2828 | 0.040 |
Why?
|
Activating Transcription Factor 4 | 1 | 2019 | 86 | 0.040 |
Why?
|
Protein Binding | 2 | 2022 | 9301 | 0.040 |
Why?
|
Biosynthetic Pathways | 1 | 2019 | 138 | 0.040 |
Why?
|
Integrins | 1 | 2022 | 838 | 0.040 |
Why?
|
Interferon-alpha | 1 | 2022 | 909 | 0.040 |
Why?
|
Tissue Culture Techniques | 1 | 2019 | 286 | 0.040 |
Why?
|
Nitroimidazoles | 1 | 2019 | 118 | 0.040 |
Why?
|
Germ Cells | 1 | 2022 | 646 | 0.040 |
Why?
|
Spliceosomes | 1 | 2018 | 116 | 0.040 |
Why?
|
Nucleotides | 1 | 2020 | 453 | 0.040 |
Why?
|
S-Adenosylmethionine | 1 | 2019 | 219 | 0.040 |
Why?
|
Fluorescent Antibody Technique | 1 | 2022 | 2469 | 0.040 |
Why?
|
Protein Biosynthesis | 1 | 2024 | 2091 | 0.040 |
Why?
|
Receptors, Glucocorticoid | 1 | 2019 | 308 | 0.040 |
Why?
|
Multienzyme Complexes | 1 | 2020 | 663 | 0.040 |
Why?
|
Colorectal Neoplasms | 1 | 2017 | 6961 | 0.030 |
Why?
|
Urothelium | 1 | 2019 | 275 | 0.030 |
Why?
|
Protein Subunits | 1 | 2020 | 940 | 0.030 |
Why?
|
Cullin Proteins | 1 | 2018 | 180 | 0.030 |
Why?
|
Etoposide | 1 | 2018 | 636 | 0.030 |
Why?
|
Protein Isoforms | 1 | 2021 | 1716 | 0.030 |
Why?
|
BRCA2 Protein | 1 | 2022 | 802 | 0.030 |
Why?
|
Transforming Growth Factor beta | 1 | 2024 | 1996 | 0.030 |
Why?
|
MicroRNAs | 1 | 2012 | 3787 | 0.030 |
Why?
|
Polymerase Chain Reaction | 2 | 2019 | 6059 | 0.030 |
Why?
|
Cell Hypoxia | 1 | 2019 | 656 | 0.030 |
Why?
|
Structure-Activity Relationship | 1 | 2022 | 3051 | 0.030 |
Why?
|
Pilot Projects | 2 | 2022 | 8724 | 0.030 |
Why?
|
Hydrogels | 1 | 2021 | 729 | 0.030 |
Why?
|
Gene Expression Regulation | 1 | 2014 | 11906 | 0.030 |
Why?
|
Cell Cycle | 2 | 2015 | 2920 | 0.030 |
Why?
|
Gene Knockdown Techniques | 1 | 2020 | 1602 | 0.030 |
Why?
|
Basic Helix-Loop-Helix Transcription Factors | 1 | 2021 | 1138 | 0.030 |
Why?
|
Carboplatin | 1 | 2018 | 787 | 0.030 |
Why?
|
Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2019 | 620 | 0.030 |
Why?
|
Molecular Imaging | 1 | 2022 | 822 | 0.030 |
Why?
|
Biological Evolution | 1 | 2020 | 1075 | 0.030 |
Why?
|
Body Composition | 1 | 2024 | 2441 | 0.030 |
Why?
|
Fanconi Anemia | 1 | 2017 | 327 | 0.030 |
Why?
|
DNA | 2 | 2019 | 7193 | 0.030 |
Why?
|
Pharmacology | 1 | 2014 | 97 | 0.030 |
Why?
|
Adult | 8 | 2021 | 223139 | 0.030 |
Why?
|
Cell Membrane | 1 | 2023 | 3635 | 0.030 |
Why?
|
Carcinoma, Acinar Cell | 1 | 2014 | 62 | 0.030 |
Why?
|
Extracellular Matrix | 1 | 2021 | 1727 | 0.030 |
Why?
|
Proportional Hazards Models | 2 | 2019 | 12529 | 0.030 |
Why?
|
Breast | 1 | 2022 | 1950 | 0.030 |
Why?
|
Fluorescent Dyes | 1 | 2022 | 1928 | 0.030 |
Why?
|
Carcinoma, Large Cell | 1 | 2014 | 114 | 0.030 |
Why?
|
Phosphorylation | 1 | 2024 | 8292 | 0.030 |
Why?
|
Gene Knockout Techniques | 1 | 2016 | 800 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-met | 1 | 2017 | 562 | 0.030 |
Why?
|
Chromosome Breakpoints | 1 | 2013 | 93 | 0.030 |
Why?
|
Paclitaxel | 1 | 2020 | 1727 | 0.030 |
Why?
|
Clone Cells | 1 | 2016 | 1671 | 0.030 |
Why?
|
Neoplasms, Glandular and Epithelial | 1 | 2017 | 488 | 0.030 |
Why?
|
Antibodies, Monoclonal | 1 | 2010 | 9237 | 0.030 |
Why?
|
Death | 1 | 2017 | 686 | 0.030 |
Why?
|
Carcinoid Tumor | 1 | 2014 | 225 | 0.030 |
Why?
|
Thionucleosides | 1 | 2012 | 12 | 0.020 |
Why?
|
Thioguanine | 1 | 2012 | 45 | 0.020 |
Why?
|
Deoxyadenosines | 1 | 2012 | 27 | 0.020 |
Why?
|
Internationality | 1 | 2018 | 1007 | 0.020 |
Why?
|
Piperidines | 1 | 2021 | 1664 | 0.020 |
Why?
|
Proto-Oncogene Proteins | 1 | 2024 | 4521 | 0.020 |
Why?
|
Interleukin-6 | 1 | 2022 | 3227 | 0.020 |
Why?
|
History, 20th Century | 1 | 2020 | 2762 | 0.020 |
Why?
|
Urethral Neoplasms | 1 | 2012 | 37 | 0.020 |
Why?
|
British Columbia | 1 | 2012 | 238 | 0.020 |
Why?
|
Chromatin Immunoprecipitation | 1 | 2014 | 856 | 0.020 |
Why?
|
Models, Molecular | 1 | 2022 | 5382 | 0.020 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2020 | 3546 | 0.020 |
Why?
|
Triazoles | 1 | 2017 | 902 | 0.020 |
Why?
|
Sensitivity and Specificity | 2 | 2019 | 14645 | 0.020 |
Why?
|
Histones | 1 | 2021 | 2591 | 0.020 |
Why?
|
Female | 7 | 2022 | 396233 | 0.020 |
Why?
|
Benzodiazepines | 1 | 2017 | 1136 | 0.020 |
Why?
|
Tubulin | 1 | 2014 | 694 | 0.020 |
Why?
|
Hospice Care | 1 | 2017 | 678 | 0.020 |
Why?
|
HEK293 Cells | 1 | 2020 | 4263 | 0.020 |
Why?
|
Nomograms | 1 | 2012 | 235 | 0.020 |
Why?
|
Apoptosis Regulatory Proteins | 1 | 2015 | 1150 | 0.020 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2015 | 1777 | 0.020 |
Why?
|
RNA, Small Interfering | 1 | 2019 | 3424 | 0.020 |
Why?
|
Risk | 1 | 2021 | 9599 | 0.020 |
Why?
|
Gene Fusion | 1 | 2012 | 357 | 0.020 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2018 | 2057 | 0.020 |
Why?
|
Muscle, Skeletal | 1 | 2024 | 4959 | 0.020 |
Why?
|
Diagnostic Imaging | 1 | 2023 | 3530 | 0.020 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2012 | 702 | 0.020 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2018 | 2877 | 0.020 |
Why?
|
Flow Cytometry | 1 | 2019 | 5881 | 0.020 |
Why?
|
Liver | 1 | 2024 | 7559 | 0.020 |
Why?
|
CpG Islands | 1 | 2013 | 1207 | 0.020 |
Why?
|
Clinical Trials, Phase I as Topic | 1 | 2010 | 329 | 0.020 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2014 | 2510 | 0.020 |
Why?
|
Cell Division | 1 | 2015 | 4466 | 0.020 |
Why?
|
Genotype | 1 | 2022 | 13028 | 0.020 |
Why?
|
Blotting, Western | 1 | 2015 | 5020 | 0.020 |
Why?
|
Magnetic Resonance Imaging | 3 | 2021 | 36548 | 0.020 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2010 | 637 | 0.020 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2021 | 4649 | 0.020 |
Why?
|
Esophageal Neoplasms | 1 | 2017 | 1659 | 0.020 |
Why?
|
Cause of Death | 1 | 2017 | 3715 | 0.020 |
Why?
|
Gene Frequency | 1 | 2013 | 3623 | 0.020 |
Why?
|
Proteomics | 1 | 2019 | 3907 | 0.020 |
Why?
|
Tissue and Organ Procurement | 1 | 2013 | 988 | 0.020 |
Why?
|
Cluster Analysis | 1 | 2012 | 2718 | 0.020 |
Why?
|
Colonic Neoplasms | 1 | 2017 | 2532 | 0.020 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2017 | 2040 | 0.010 |
Why?
|
Research Design | 1 | 2020 | 6206 | 0.010 |
Why?
|
United States | 2 | 2024 | 72920 | 0.010 |
Why?
|
Lymphatic Metastasis | 1 | 2012 | 2890 | 0.010 |
Why?
|
Transfection | 1 | 2012 | 5739 | 0.010 |
Why?
|
Cancer Vaccines | 1 | 2011 | 1042 | 0.010 |
Why?
|
Blood Glucose | 1 | 2018 | 6421 | 0.010 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2020 | 10380 | 0.010 |
Why?
|
Cell Movement | 1 | 2015 | 5196 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2013 | 16040 | 0.010 |
Why?
|
Head and Neck Neoplasms | 1 | 2017 | 2926 | 0.010 |
Why?
|
Databases, Factual | 1 | 2018 | 8062 | 0.010 |
Why?
|
Cost-Benefit Analysis | 1 | 2015 | 5531 | 0.010 |
Why?
|
Decision Support Techniques | 1 | 2012 | 2006 | 0.010 |
Why?
|
Pandemics | 1 | 2022 | 8725 | 0.010 |
Why?
|
Ovarian Neoplasms | 1 | 2017 | 4904 | 0.010 |
Why?
|
Radiopharmaceuticals | 1 | 2010 | 2702 | 0.010 |
Why?
|
Age Factors | 1 | 2016 | 18386 | 0.010 |
Why?
|
Genetic Variation | 1 | 2014 | 6612 | 0.010 |
Why?
|
Incidence | 1 | 2016 | 21513 | 0.010 |
Why?
|
Child, Preschool | 1 | 2017 | 42511 | 0.010 |
Why?
|
Algorithms | 1 | 2014 | 14066 | 0.010 |
Why?
|
Genome-Wide Association Study | 1 | 2013 | 12803 | 0.010 |
Why?
|
Risk Factors | 1 | 2020 | 74857 | 0.010 |
Why?
|